Oruka Therapeutics (ORKA) COO gets 130,000 options and 32,500-share grant

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. disclosed that Chief Operating Officer Laura Sandler received new equity awards on January 23, 2026. She was granted 32,500 shares of common stock at a price of $0 per share, increasing her directly held common stock to 237,584 shares. The stock grant vests in 1/16 increments on each March 14, June 14, September 14 and December 14.

She also received an employee stock option covering 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. This option vests as to 1/48 of the underlying shares monthly starting from January 1, 2026, and is held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sandler Laura Lee

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	130,000	$0.00	--
Grant/Award	Common Stock	32,500	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 130,000 shares (Direct); Common Stock — 237,584 shares (Direct)

Footnotes (1)

1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandler Laura Lee

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		32,500(1)	A	$0	237,584	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$34.39	01/23/2026		A		130,000		(2)	01/22/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).

2. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ORKA report for Laura Sandler?

Oruka Therapeutics reported that Chief Operating Officer Laura Sandler received a grant of 32,500 shares of common stock and an option for 130,000 shares on January 23, 2026.

How many Oruka Therapeutics (ORKA) shares does Laura Sandler now directly own?

After the reported transaction, Laura Sandler directly beneficially owns 237,584 shares of Oruka Therapeutics common stock.

What are the key terms of Laura Sandlers new stock option at Oruka Therapeutics (ORKA)?

The new employee stock option covers 130,000 shares at an exercise price of $34.39 per share, expires on January 22, 2036, and vests in 1/48 monthly installments from January 1, 2026.

How does the 32,500-share Oruka Therapeutics stock grant to Laura Sandler vest?

The 32,500-share common stock grant to Laura Sandler vests as to 1/16 of the shares on each March 14, June 14, September 14, and December 14, or the preceding trading day if necessary.

Is Laura Sandlers ownership in Oruka Therapeutics (ORKA) direct or indirect?

The Form 4 indicates that both the 237,584 common shares and the 130,000 stock options reported for Laura Sandler are held with direct ownership.

What role does Laura Sandler hold at Oruka Therapeutics (ORKA)?

Laura Sandler is reported as an officer of Oruka Therapeutics, serving as the companys Chief Operating Officer.